Cadmus Animal Health

Cadmus Animal Health is a biotechnology company developing an immunotherapeutic to treat chronic periodontal disease in companion animals. Founded in 2021 and headquartered in Auckland, New Zealand, the company is focused on creating a targeted treatment that addresses the underlying bacterial cause of the disease, specifically the bacterium Porphyromonas, to improve the oral health of pets. Cadmus Animal Health operates in the life sciences and drug discovery sectors within the broader animal health industry.

As a venture capital-backed, seed-stage startup, the company has secured funding from investors including Brandon Capital and the Booster Innovation Fund (BIF). In August 2025, BIF announced an investment of up to $500,000, which followed an initial investment of $250,000. Duncan Mackintosh, a Senior Investment Manager at Brandon Capital with a background in clinical veterinary practice, serves as a director for the company.

The company's business model centers on the research and development of its specialized drug, aiming to provide veterinarians with a novel solution for a common and chronic condition in companion animals. By focusing on an immunotherapeutic approach, Cadmus targets a specific pathogen, differentiating its product from broader treatments.

Keywords: animal health, biotechnology, immunotherapeutics, periodontal disease, companion animals, veterinary medicine, drug discovery, life sciences, pet healthcare, Porphyromonas, New Zealand startup, venture capital, oral health pets, veterinary drugs, animal biotech